Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress
Open Access
- 22 August 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 92 (3) , 375-384
Abstract
Mutations in the ALK1 gene, coding for an endothelial-specific receptor of the transforming growth factor-β superfamily, are the underlying cause of hereditary haemorrhagic telangiectasia type 2, but are also associated with familial pulmonary hypertension (PH). We assessed the lung vasculature of mice with a heterozygous deletion of Alk1 (Alk1+/−) for disease manifestations and levels of reactive O2 species (ROS) implicated in both disorders. Several signs of PH, including elevated right ventricular (RV) systolic pressure leading to RV hypertrophy, reduced vascular density, and increased thickness and outward remodelling of pulmonary arterioles, were observed in 8- to 18-week-old Alk1+/− mice relative to wild-type littermate controls. Higher ROS lung levels were also documented. At 3 weeks, Alk1+/− mice were indistinguishable from controls and were prevented from subsequently developing PH when treated with the anti-oxidant Tempol for 6 weeks, confirming a role for ROS in pathogenesis. Levels of NADPH oxidases and superoxide dismutases were higher in adults than newborns, but unchanged in Alk1+/− mice vs. controls. Prostaglandin metabolites were also normal in adult Alk1+/− lungs. In contrast, NO production was reduced, while endothelial NO synthase (eNOS)-dependent ROS production was increased in adult Alk1+/− mice. Pulmonary near resistance arteries from adult Alk1+/− mice showed less agonist-induced force and greater acetylcholine-induced relaxation; the later was normalized by catalase or Tempol treatment. The increased pulmonary vascular remodelling in Alk1+/− mice leads to signs of PH and is associated with eNOS-dependent ROS production, which is preventable by anti-oxidant treatment.Keywords
This publication has 37 references indexed in Scilit:
- Hereditary haemorrhagic telangiectasia: a clinical and scientific reviewEuropean Journal of Human Genetics, 2009
- BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesisJournal of Cell Science, 2007
- Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cellsBlood, 2006
- Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of diseaseJournal of Medical Genetics, 2005
- Interaction and functional interplay between endoglin and ALK‐1, two components of the endothelial transforming growth factor‐β receptor complexJournal of Cellular Physiology, 2005
- Transforming Growth Factor-β Receptor Mutations and Pulmonary Arterial Hypertension in ChildhoodCirculation, 2005
- Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic TelangiectasiaNew England Journal of Medicine, 2001
- Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative.Journal of Clinical Investigation, 1997
- The Activin Receptor-Like Kinase 1 Gene: Genomic Structure and Mutations in Hereditary Hemorrhagic Telangiectasia Type 2The American Journal of Human Genetics, 1997
- Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1Nature Genetics, 1994